{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-35","upperLimit":"-5","value":"-20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"For the surgical study, Ki67 will be evaluated in paired pre-treatment tumor (diagnostic) and post-treatment tumor (recurrent) tissue in consenting patients to assess percent change. The percent of Ki67 in tumor tissues will be measured and the result is presented as the percent of Ki67 in post-treatment tumor minus the percent of Ki67 measured in pre-treatment tumor.","dispersionType":"Full Range","groups":[{"description":"Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 at 120 mg/m2/day before surgery","id":"OG000","title":"Surgical"}],"paramType":"MEDIAN","populationDescription":"Consented patients in surgical study with pre-treatment tumor and post-treatment tumor tissue available","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Percent Change in ki67 Between Archival and Post-treatment Tissue","type":"SECONDARY","unitOfMeasure":"Change of Percentage of Ki67 in Tumor"}